Literature DB >> 25458605

The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review.

Terence Ng1, Mint Chan1, Chiea Chuen Khor2, Han Kiat Ho1, Alexandre Chan3.   

Abstract

A systematic review was performed to describe the findings from 19 genetic association studies that have examined the genetic variants underlying four common treatment-induced chronic and late toxicities in breast cancer patients, and to evaluate the quality of reporting. Three out of 5 studies found an association between HER2 lle655Val polymorphisms and trastuzumab-induced cardiotoxicity. Two studies found a positive association between cognitive impairment and the Val allele of the COMT gene and the ε4 allele of the apolipoprotein E gene. Genetic associations were established between fatigue and the G/G genotype of IL6-174 and TNF-308, and the Met allele of the COMT gene in 4 studies. Among studies (N=8) that evaluated the genetic associations underlying peripheral neuropathy, CYP2C8∗3 variant is commonly reported as the associated gene. Most studies failed to conform to the major criteria listed in the STREGA guidelines, with a lack of transparent reporting of methods and results.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cardiotoxicity; Cognitive dysfunction; Fatigue; Genetic association; Peripheral neuropathy

Mesh:

Substances:

Year:  2014        PMID: 25458605     DOI: 10.1016/j.ctrv.2014.10.001

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  9 in total

Review 1.  Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.

Authors:  Alexandre Chan; Daniel L Hertz; Manuel Morales; Elizabeth J Adams; Sharon Gordon; Chia Jie Tan; Nathan P Staff; Jayesh Kamath; Jeong Oh; Shivani Shinde; Doreen Pon; Niharkia Dixit; James D'Olimpio; Cristina Dumitrescu; Margherita Gobbo; Kord Kober; Samantha Mayo; Linda Pang; Ishwaria Subbiah; Andreas S Beutler; Katherine B Peters; Charles Loprinzi; Maryam B Lustberg
Journal:  Support Care Cancer       Date:  2019-07-30       Impact factor: 3.603

2.  Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

Authors:  Helena Earl; Louise Hiller; Anne-Laure Vallier; Shrushma Loi; Karen McAdam; Luke Hughes-Davies; Daniel Rea; Donna Howe; Kerry Raynes; Helen B Higgins; Maggie Wilcox; Chris Plummer; Betania Mahler-Araujo; Elena Provenzano; Anita Chhabra; Sophie Gasson; Claire Balmer; Jean E Abraham; Carlos Caldas; Peter Hall; Bethany Shinkins; Christopher McCabe; Claire Hulme; David Miles; Andrew M Wardley; David A Cameron; Janet A Dunn
Journal:  Health Technol Assess       Date:  2020-08       Impact factor: 4.014

Review 3.  Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.

Authors:  Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann
Journal:  Drug Saf       Date:  2022-05-23       Impact factor: 5.606

4.  Translational genomic research: the role of genetic polymorphisms in MBSR program among breast cancer survivors (MBSR[BC]).

Authors:  Jong Y Park; Cecile A Lengacher; Richard R Reich; Carissa B Alinat; Sophia Ramesar; Alice Le; Carly L Paterson; Michelle L Pleasant; Hyun Y Park; John Kiluk; Hyo Han; Roohi Ismail-Khan; Kevin E Kip
Journal:  Transl Behav Med       Date:  2019-07-16       Impact factor: 3.626

5.  Trastuzumab-associated cardiac events in the Persephone trial.

Authors:  Helena M Earl; Anne-Laure Vallier; Janet Dunn; Shrushma Loi; Emma Ogburn; Karen McAdam; Luke Hughes-Davies; Adrian Harnett; Jean Abraham; Andrew Wardley; David A Cameron; David Miles; Ioannis Gounaris; Chris Plummer; Louise Hiller
Journal:  Br J Cancer       Date:  2016-11-22       Impact factor: 7.640

6.  An Evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment: A Prospective, Longitudinal Study.

Authors:  Alexandre Chan; Angie Yeo; Maung Shwe; Chia Jie Tan; Koon Mian Foo; Pat Chu; Chiea Chuen Khor; Han Kiat Ho
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

7.  Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer.

Authors:  Yosef Landman; Salomon Marcello Stemmer; Aaron Sulkes; Victoria Neiman; Tal Granot; Daniel Hendler; Mordechai Reuven Kramer; Karen Gelmon; Rinat Yerushalmi
Journal:  J Oncol       Date:  2019-10-28       Impact factor: 4.375

8.  A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol.

Authors:  Anukriti Sharma; Ken B Johnson; Bihua Bie; Emily E Rhoades; Alper Sen; Yuri Kida; Jennifer Hockings; Alycia Gatta; Jacqueline Davenport; Connie Arcangelini; Jennifer Ritzu; Jennifer DeVecchio; Ron Hughen; Mei Wei; G Thomas Budd; N Lynn Henry; Charis Eng; Joseph Foss; Daniel M Rotroff
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 9.  Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity.

Authors:  Xinyu Yang; Guoping Li; Tao Yang; Manke Guan; Na An; Fan Yang; Qianqian Dai; Changming Zhong; Changyong Luo; Yonghong Gao; Saumya Das; Yanwei Xing; Hongcai Shang
Journal:  Oxid Med Cell Longev       Date:  2020-10-13       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.